Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 860,292
  • Shares Outstanding, K 45,470
  • Annual Sales, $ 25,180 K
  • Annual Income, $ -22,290 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta 4.00
  • Price/Sales 33.34
  • Price/Cash Flow N/A
  • Price/Book 12.28

Options Overview Details

View History
  • Implied Volatility 115.57% ( +3.99%)
  • Historical Volatility 84.22%
  • IV Percentile 50%
  • IV Rank 29.80%
  • IV High 279.80% on 09/20/24
  • IV Low 45.85% on 05/15/24
  • Put/Call Vol Ratio 0.36
  • Today's Volume 763
  • Volume Avg (30-Day) 2,498
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 71,418
  • Open Int (30-Day) 75,512

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.30
  • Low Estimate -0.37
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -1,550.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.77 +3.88%
on 11/13/24
22.90 -23.93%
on 10/30/24
-3.15 (-15.31%)
since 10/21/24
3-Month
3.98 +337.69%
on 09/06/24
23.40 -25.56%
on 10/15/24
+12.84 (+280.35%)
since 08/21/24
52-Week
2.90 +500.69%
on 12/01/23
23.40 -25.56%
on 10/15/24
+14.50 (+496.58%)
since 11/21/23

Most Recent Stories

More News
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

CAPR : 17.45 (-7.77%)
Capricor: Q3 Earnings Snapshot

Capricor: Q3 Earnings Snapshot

CAPR : 17.45 (-7.77%)
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

CAPR : 17.45 (-7.77%)
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

CAPR : 17.45 (-7.77%)
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

CAPR : 17.45 (-7.77%)
Insider Stock Research: New Fortress Energy, Marvell, and More

October has seen a flurry of insider trading activity across multiple sectors, with key executives making significant stock purchases. New Fortress Energy’s (

PLAY : 34.67 (+1.23%)
DKL : 39.78 (+0.38%)
RNAC : 16.78 (-0.94%)
COHR : 105.78 (+2.32%)
NEOG : 14.96 (+0.40%)
WOR : 39.19 (+1.50%)
NFE : 9.31 (+1.42%)
STTK : 1.0350 (-6.76%)
MRVL : 90.38 (+0.58%)
CAPR : 17.45 (-7.77%)
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

CAPR : 17.45 (-7.77%)
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

CAPR : 17.45 (-7.77%)
Capricor Therapeutics Announces Proposed Public Offering of Common Stock

CAPR : 17.45 (-7.77%)
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

CAPR : 17.45 (-7.77%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 20.64
2nd Resistance Point 20.01
1st Resistance Point 19.47
Last Price 17.45
1st Support Level 18.30
2nd Support Level 17.67
3rd Support Level 17.13

See More

52-Week High 23.40
Last Price 17.45
Fibonacci 61.8% 15.57
Fibonacci 50% 13.15
Fibonacci 38.2% 10.73
52-Week Low 2.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar